|
**Overview**: Autoimmune Liver Diseases IgG Panel**Introduction**: The Autoimmune Liver Diseases IgG Panel is a diagnostic tool designed to screen for autoimmune liver diseases using serum samples. In India, autoimmune liver diseases (AIH, PBC, PSC overlap) affect 1-5 per 100,000, with AIH type 1 common (ANA/ASMA positive) and type 2 in children (anti-LKM1). High prevalence in northern states, association with viral hepatitis, and underdiagnosis in rural areas due to nonspecific fatigue/jaundice. High morbidity from delayed diagnosis leading to cirrhosis. Per hepatology practices aligned with ICMR and INASL guidelines, the test employs immunoassay for antibody detection over 1-2 days with high sensitivity/specificity, valuable for confirming autoimmunity and guiding therapy. This diagnostic falls under liver disorder screening and targets patients with unexplained liver disease, addressing accurate detection to prevent progression. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing cirrhosis burden. Its serum-based approach ensures reliable detection.**Other Names**: Auto Liver Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Expanded for multi-antibody screening; in India, prominence with rising AIH cases.**Purpose**: The test screens for 9 parameters including ANA to guide autoimmune liver disease assessment, confirm autoimmunity, inform treatment.**Test Parameters**: 1. ANA, 2. Anti-Smooth Muscle Ab, 3. Anti-LKM1, 4. Anti-Mitochondrial Ab, 5. Anti-SLA/LP, 6. Anti-Sp100, 7. Anti-gp210, 8. Anti-LC1, 9. Anti-Factin.**Pretest Condition**: No fasting required; patients should report fatigue, jaundice, arthralgia, or elevated liver enzymes.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on jaundice, fatigue, family autoimmune history, viral hepatitis exposure.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated autoimmune liver disease including cirrhosis, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent viral hepatitis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate autoimmune liver disease, necessitating specialist input. Negative may require follow-up if liver enzymes elevated.**Specialist Consultation**: Hepatologists should be consulted for management.**Additional Supporting Tests**: Liver biopsy, IgG levels for confirmation.**Test Limitations**: May overlap with other liver diseases; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, Autoimmune Liver Studies India 2023. |
